Disappointing 2016 bottom-line vs. a healthy Q1 2017
During Q1 2017, Unimed’s revenues increased by 10.7% to TND16.406m vs. TND14.814m during Q1 2016. This growth is mainly due to a 16.1% progression in pharmaceutical sales to TND5.411m and a 36.6% rise in export outsourcing sales to TND5.016m. Sales to hospitals also increased by 11.3% to TND5.05m vs. TND4.536m as of 31/03/2016. Nevertheless, export revenues were cut in half to reach TND0.89m. The production was up by 5.3% to 50.8 million units.
AlphaMena is the MENA stocks leader in independent equity research, covering 142. MENA securities spanning across 19 sectors and 8 countries relaying on a team of 11 analysts. The breadth of coverage allows AlphaMena to formulate a coherent view on markets, sectors and to highlight the best investments in Mena zone using a robust homogeneous and transparent methodology, enabling pure and pertinent comparisons based on financial and extra-financial criteria.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.